Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure

Egyptian Heart Journal

Volumn 63, Issue 2, 2011, Pages 79-85

  Mansour, Sherief ^a   Youssef, Amr ^a   Rayan, Mona ^a   Ayman Saleh, M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Dilated cardiomyopathy; Heart failure; Ivabradine

Indexed keywords

CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; SPIRONOLACTONE;

ADD ON THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CARDIAC PATIENT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG USE; ECHOCARDIOGRAPHY; EVENING DOSAGE; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART RATE; HOSPITALIZATION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORNING DOSAGE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTOR VARIABLE; QUALITY OF LIFE; RANDOMIZATION; SCREENING;

EID: 84879191629     PISSN: 11102608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2011.09.001     Document Type: Article

References (27)

1. Dickstein K., Cohen-Solal A., Filippatos G., Mac Murray J.J., Ponikowski P., Poole-Wilson P.A., et al. ESC guidelines for the diagnosis, treatment of acute, chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 2008(10):933-989.
2. Birks E.J., Tansley P.D., Hardy J., George R.S., Bowles C.T., Burke M., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355:1873-1884.
3. Jhund P.S., Macintyre K., Simpson C.R., Lewsey J.D., Stewart S., Redpath A., et al. Long-term trends in first hospitalization for heart failure, subsequent survival between and 2003: a population study of 5.1 million people. Circulation 1986, 2009(119):515-523.
4. Schaufelberger M., Swedberg K., Koster M., Rosen M., Rosengren A. Decreasing one-year mortality, hospitalization rates for heart failure in Sweden; data from the Swedish hospital discharge registry to 2000. Eur Heart J 1988, 2004(25):300-307.
5. Shafazand M., Schaufelberger M., Lappas G., Swedberg K., Rosengren A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish hospital discharge registry. Eur Heart J 2009, 30:671-678.
6. Benetos A., Rudnichi A., Thomas F., Safar M., Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999, 33:44-52.
7. Chang M., Havlik R.J., Corti M.C., Chaves P.H., Fried L.P., Guralnik J.M. Relation of heart rate at rest and mortality in the Women's health and aging study. Am J Cardiol 2003, 92:1294-1299.
8. Jouven X., Empana J.P., Schwartz P.J., Desnos M., Courbon D., Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005, 352:1951-1958.
9. Dyer A.R., Persky V., Stamler J., Paul O., Shekelle R.B., Berkson D.M., et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980, 112:736-749.
10. Goldberg R.J., Larson M., Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med 1996, 156:505-509.
11. Kannel W.B., Kannel C., Paffenbarger R.S.J.R., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
12. Gheorghiade M., Colucci W.S., Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003, 107:1570-1575.
13. Ragueneau I., Laveille C., Jochemsen R., Resplandy G., Funck-Brentano C., Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998, 64:192-203.
14. Singh B. Impact of reduced heart rate on cardiovascular disorders: focus on chronic stable angina. Selective, specific If channel inhibition in cardiology 2004, Science Press, London, UK, pp. 25-36.
15. DiFrancesco D., Camm A.J. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004, 64:1757-1765.
16. Mulder P., Barbier S., Chagraoui A., Richard V., Henry J.P., Lallemand F., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004, 109:1674-1679.
17. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816.
18. Rector T.S., Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992, 124:1017-1025.
19. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
20. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., Cas L.D. Differential effects of beta-blockers in patients with heart failure: a prospective randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000, 102:546-551.
21. Krum H., Sacker-Berstein J.D., Goldsmith R.L., Kukin M.L., Schwartz B., Penn J., et al. Double-blind placebo-controlled study of the long-term efficacy of carvediolol in patients with severe chronic heart failure. Circulation 1995, 92:1499-1506.
22. Cohn J.N., Fowler M.B., Bristow M.R., Colucci W.S., Gilbert E.M., Kinhal V., et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997, 3:173-179.
23. Flannery G., Gehrig-Mills R., Billah B., Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008, 101:865-869.
24. Fowler M.B., Vera-Llonvh M., Oster G., Bristow M.R., Cohn J.N., Colucci W.S., et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. J Am Coll Cardiol 2001, 37:1692-1699.
25. Berrie C. Haemodynamic effects of ivabradine, a pure heart rate-lowering agent in patients with severe chronic heart failure receiving beta-blockers. Presented at: Heart Failure Congress 2008, Milan, Italy.
26. McAlister F.A., Wiebe N., Ezekowitz J.A., Leung A.A., Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150:784-794.
27. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817-821.